0001209191-21-007827.txt : 20210204 0001209191-21-007827.hdr.sgml : 20210204 20210204173204 ACCESSION NUMBER: 0001209191-21-007827 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210204 FILED AS OF DATE: 20210204 DATE AS OF CHANGE: 20210204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dornan David CENTRAL INDEX KEY: 0001821353 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39988 FILM NUMBER: 21592427 MAIL ADDRESS: STREET 1: C/O BOLT BIOTHERAPEUTICS, INC. STREET 2: 640 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bolt Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001641281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472804636 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-665-9295 MAIL ADDRESS: STREET 1: 900 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: Bolt Therapeutics, Inc. DATE OF NAME CHANGE: 20150504 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-02-04 0 0001641281 Bolt Biotherapeutics, Inc. BOLT 0001821353 Dornan David C/O BOLT BIOTHERAPEUTICS, INC. 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 0 1 0 0 Chief Scientific Officer Stock Option (Right to Buy) 2.03 2028-01-16 Common Stock 64571 D Stock Option (Right to Buy) 2.03 2028-04-03 Common Stock 13702 D Stock Option (Right to Buy) 2.24 2029-01-10 Common Stock 26460 D Stock Option (Right to Buy) 2.73 2029-11-13 Common Stock 78571 D Stock Option (Right to Buy) 4.34 2030-09-02 Common Stock 12142 D Stock Option (Right to Buy) 4.34 2030-09-02 Common Stock 35714 D 1/4th of the shares subject to the option shall vest on the one year anniversary of December 1, 2017 (the "Vesting Commencement Date"), and 1/48th of the shares shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a service provider through each such date. 1/4th of the shares subject to the option shall vest on the one year anniversary of February 14, 2018 (the "February 2018 Vesting Commencement Date"), and 1/48th of the shares shall vest each month thereafter on the same day of the month as the February 2018 Vesting Commencement Date, subject to the Reporting Person continuing to be a service provider through each such date. 1/4th of the shares subject to the option shall vest on the one year anniversary of July 23, 2018 (the "July 2018 Vesting Commencement Date"), and 1/48th of the shares shall vest each month thereafter on the same day of the month as the July 2018 Vesting Commencement Date, subject to the Reporting Person continuing to be a service provider through each such date. 1/48th of the shares subject to the option shall vest on the one month anniversary of July 2, 2019 (the "July 2019 Vesting Commencement Date") and 1/48th of the shares shall vest each month thereafter on the same day of the month as the July 2019 Vesting Commencement Date, subject to the Reporting Person continuing to be a service provider to the Issuer through each such date. For so long as the Reporting Person continuously provides services to the Issuer (or any subsidiary or parent of the Issuer) as an employee, officer, director, contractor or consultant, through the applicable vesting dates, this option will vest and become exercisable as follows: (a) prior to September 3, 2020 (the "September 2020 Vesting Commencement Date"), this option will not be vested or exercisable as to any of the shares subject to the option; and (b) following the September 2020 Vesting Commencement Date, this option will become vested and exercisable with respect to 1/48th of the shares subject to the option when the Reporting Person completes each month of continuous service following the September 2020 Vesting Commencement Date. For so long as the Reporting Person continuously provides services to the Issuer (or any subsidiary or parent of the Issuer) as an employee, officer, director, contractor or consultant, through the applicable vesting dates, this option will vest and become exercisable as follows: (a) prior to January 15, 2021 (the "January 2021 Vesting Commencement Date"), this option will not be vested or exercisable as to any of the shares subject to the option; and (b) following the January 2021 Vesting Commencement Date, this option will become vested and exercisable with respect to 1/48th of the shares subject to the option when the Reporting Person completes each month of continuous service following the January 2021 Vesting Commencement Date. Exhibit 24 - Power of Attorney /s/ Brian Woodard, Attorney-in-Fact 2021-02-04 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY
Know all by these presents that the undersigned hereby constitutes and appoints
each of William Quinn of Bolt Biotherapeutics, Inc. (the "Company") and John
McKenna, Kate Nichols, Colleen Badgley, Michael Perretta, Tess Morgan and Brian
Woodard of Cooley LLP, signing individually, the undersigned's true and lawful
attorneys-in fact and agents to:
(1) prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934 or any rule or regulation thereunder;

(2) prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such Forms with the SEC and any stock exchange,
self-regulatory association or any other authority; and

(4) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, and
their substitutes, in serving in such capacity at the request of the
undersigned, are not assuming (nor is the Company assuming) any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated: August 4, 2020


By: /s/ David Dornan	 		David Dornan
	Signature 			Printed Name